218 related articles for article (PubMed ID: 29122697)
1. Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia.
Park SY; Lee EJ; Kim T; Yu SN; Park KH; Lee MS; Park SY; Jeon MH; Kim TH; Choo EJ
Int J Antimicrob Agents; 2018 Mar; 51(3):407-412. PubMed ID: 29122697
[TBL] [Abstract][Full Text] [Related]
2. Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections.
Song JY; Cheong HJ; Choi WS; Heo JY; Noh JY; Kim WJ
J Med Microbiol; 2011 May; 60(Pt 5):605-611. PubMed ID: 21233298
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Mortality in Children with
Choe YJ; Lee HJ; Choi EH
Microb Drug Resist; 2019 Oct; 25(8):1210-1218. PubMed ID: 31120349
[No Abstract] [Full Text] [Related]
4. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.
Zheng YL; Wan YF; Zhou LY; Ye ML; Liu S; Xu CQ; He YQ; Chen JH
Am J Infect Control; 2013 Jul; 41(7):e59-63. PubMed ID: 23523521
[TBL] [Abstract][Full Text] [Related]
5. Colistin treatment in carbapenem-resistant Acinetobacter baumannii pneumonia patients: Incidence of nephrotoxicity and outcomes.
Kwon KH; Oh JY; Yoon YS; Jeong YJ; Kim KS; Shin SJ; Chung JW; Huh HJ; Chae SL; Park SY
Int J Antimicrob Agents; 2015 Jun; 45(6):605-9. PubMed ID: 25772644
[TBL] [Abstract][Full Text] [Related]
6. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.
Du X; Xu X; Yao J; Deng K; Chen S; Shen Z; Yang L; Feng G
Am J Infect Control; 2019 Sep; 47(9):1140-1145. PubMed ID: 31003750
[TBL] [Abstract][Full Text] [Related]
7. Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center.
Choi SH; Cho EB; Chung JW; Lee MK
J Infect Chemother; 2019 Jan; 25(1):6-11. PubMed ID: 30342838
[TBL] [Abstract][Full Text] [Related]
8. Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections.
Erbay A; Idil A; Gözel MG; Mumcuoğlu I; Balaban N
Int J Antimicrob Agents; 2009 Dec; 34(6):575-9. PubMed ID: 19740628
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP
J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Acute Kidney Injury and 28-Day Mortality in Carbapenem-Resistant
Yu SN; Kim T; Park SY; Lee YM; Park KH; Lee EJ; Jeon MH; Choo EJ; Kim TH; Lee MS; Park SY
Microb Drug Resist; 2021 Aug; 27(8):1029-1036. PubMed ID: 33656377
[TBL] [Abstract][Full Text] [Related]
12. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia.
Metan G; Sariguzel F; Sumerkan B
Eur J Intern Med; 2009 Sep; 20(5):540-4. PubMed ID: 19712862
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy.
Kim YJ; Kim SI; Hong KW; Kim YR; Park YJ; Kang MW
J Korean Med Sci; 2012 May; 27(5):471-5. PubMed ID: 22563209
[TBL] [Abstract][Full Text] [Related]
14. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection.
Lee YT; Kuo SC; Yang SP; Lin YT; Tseng FC; Chen TL; Fung CP
Clin Infect Dis; 2012 Jul; 55(2):209-15. PubMed ID: 22495546
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology of carbapenem resistance in Acinetobacter baumannii complex in Germany (2014-2018): an analysis of data from the national Antimicrobial Resistance Surveillance system.
Said D; Willrich N; Ayobami O; Noll I; Eckmanns T; Markwart R
Antimicrob Resist Infect Control; 2021 Mar; 10(1):45. PubMed ID: 33648594
[TBL] [Abstract][Full Text] [Related]
16. Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases.
Özvatan T; Akalın H; Sınırtaş M; Ocakoğlu G; Yılmaz E; Heper Y; Kelebek N; İşçimen R; Kahveci F
Respirology; 2016 Feb; 21(2):363-9. PubMed ID: 26635315
[TBL] [Abstract][Full Text] [Related]
17. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.
Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C
Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of clinical characteristics and antimicrobial resistance of carbapenem-resistant Acinetobacter baumannii infections in children].
Zhang TQ; Dong L; Wang ZY; Li HY
Zhonghua Er Ke Za Zhi; 2011 Jul; 49(7):545-9. PubMed ID: 22088187
[TBL] [Abstract][Full Text] [Related]
19. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
Amat T; Gutiérrez-Pizarraya A; Machuca I; Gracia-Ahufinger I; Pérez-Nadales E; Torre-Giménez Á; Garnacho-Montero J; Cisneros JM; Torre-Cisneros J
Clin Microbiol Infect; 2018 Jun; 24(6):630-634. PubMed ID: 28970161
[TBL] [Abstract][Full Text] [Related]
20. Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities?
Lee YT; Kuo SC; Yang SP; Lin YT; Chiang DH; Tseng FC; Chen TL; Fung CP
Clin Microbiol Infect; 2013 Jul; 19(7):640-5. PubMed ID: 22967204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
